Slide 1: First nine months results
2015 First nine months results CONFERENCE CALL – 28 OCTOBER 2015
Slide 2: First nine months 2015 highlights
First nine months 2015 highlights • Revenue € 784.4 million, up 5.7% • EBITDA € 240.5 million or 30.7% of sales, up 13.0% • Operating income (EBIT) € 213.0 million or 27.2% of sales, up 18.1% • Net income € 152.5 million or 19.4% of sales, up 23.0% • Net debt € 58.2 million, a reduction of € 127.8 m
Slide 3: Main product sales
Main product sales Corporate products including drugs for rare diseases account for 60.2% of revenue (million Euro) Jan‐Sep 2015 Jan‐Sep 2014 Change % Zanidip® (lercanidipine) 89.9 86.1 4.4 Zanipress® (lercanidipine+enalapril) 49.8 46.4 7.2 Urorec® (silodosin) 50.7 42.7 18.5 Livazo® (pitavastatin) 2
Slide 4: A diversified product portfolio
A diversified product portfolio Other corporate products 13.9% Drugs for rare diseases 14.3% Livazo® 2.7% Urorec® 6.5% OTC 16.9% Zanipress® 6.3% Zanidip® 11.5% Subsidiaries’ local product portfolios 23.5% Pharmaceutical chemicals 3.3% Methadone ‐ France 3% Other revenue 1.1% Ortoton® (methocarbamol)
Slide 5: Composition of revenue by geography
Composition of revenue by geography Solid volume growth (million Euro) Jan‐Sep 2015 Jan‐Sep 2014 Change % Italy 157.4 165.6 (5.0) France 81.6 81.4 0.2 Germany 68.6 61.8 11.0 U.S.A. 60.0 42.7 40.6 Turkey 56.3 49.9 12.6 Spain 53.1 50.2 5.7 Russia, other CIS countries and Ukraine 52.0 60.0 (13.4) North
Slide 6: Geographical breakdown of pharmaceutical revenue
Geographical breakdown of pharmaceutical revenue Other international sales 16.5% (sales to licensees and exports) Italy 20.8% Other W. Europe 2.7% Other CEE 3.1% Portugal 3.8% North Africa 4.2% France 10.7% Russia, other CIS and Ukraine 6.9% Germany 9.0% Spain 7.0% Turkey 7.4% U.S.A. 7.9% Data: Firs
Slide 7: First nine months 2015 results
First nine months 2015 results Further margin growth (million Euro) Jan‐Sep 2015 Jan‐Sep 2014 Change % Revenue 784.4 742.1 5.7 Gross Profit 532.8 497.3 7.1 as % of revenue 67.9 67.0 SG&A Expenses 262.5 253.3 3.6 as % of revenue 33.5 34.2 R&D Expenses 55.2 62.0 (10.9) as % of revenue 7.0 8.3 Other In
Slide 8: First nine months 2015 results: Operating segments
First nine months 2015 results Operating segments Revenue EBIT Treatments for rare diseases 14.3% Treatments for rare diseases 22.2% Primary & specialty care Primary & specialty care 85.7% 77.8% EBIT margin on sales: Treatments for rare diseases, 42.3% Primary & Specialty care, 24.6% 8
Slide 9: Financial position and Shareholders' equity
Financial position and Shareholders’ equity (million Euro) 30 Sep 2015 31 Dec 2014 Change Cash and short‐term financial 261.3 137.0 124.3 investments Bank overdrafts and short‐term loans (11.9) (8.6) (3.4) Loans – due within one year (33.6) (28.3) (5.3) Loans – due after one year (273.9) (286.2) 12.
Slide 10: Financial projections 2015 targets
Financial projections 2015 targets 2014 2015 (million Euro) Actual Targets Revenue 987.4 ± 1,040 Operating income 231.0 ± 270 (EBIT) Net Income 161.2 ± 190 10
Slide 11: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154‐bis of the Consolidated Law on Finan